ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,814.40
-0.85%
S&P ASX All Technology
3,045.20
-2.07%
Brent Oil
83.76
0.00%
US Dollar vs AUD
1.49165
-0.03%
Bitcoin
66,905.07
-0.26%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Allarity Therapeutics Inc (ALLR)

  7. Allarity Therapeutics Inc (ALLR) News

ALLR

Allarity Therapeutics (ALLR)

Allarity Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALLR
DateTimeSourceHeadlineSymbolCompany
18/05/202406:08Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALLRAllarity Therapeutics Inc
15/05/202423:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
15/05/202406:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALLRAllarity Therapeutics Inc
15/05/202406:01GlobeNewswire Inc.Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity BalancesNASDAQ:ALLRAllarity Therapeutics Inc
10/05/202401:21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALLRAllarity Therapeutics Inc
09/05/202423:47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
09/05/202406:05Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:ALLRAllarity Therapeutics Inc
07/05/202423:30GlobeNewswire Inc.Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common StockNASDAQ:ALLRAllarity Therapeutics Inc
06/05/202423:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
06/05/202423:13Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALLRAllarity Therapeutics Inc
06/05/202422:00GlobeNewswire Inc.Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1NASDAQ:ALLRAllarity Therapeutics Inc
02/05/202422:00GlobeNewswire Inc.Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian CancerNASDAQ:ALLRAllarity Therapeutics Inc
29/04/202421:00GlobeNewswire Inc.Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price RequirementNASDAQ:ALLRAllarity Therapeutics Inc
17/04/202423:10GlobeNewswire Inc.Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)NASDAQ:ALLRAllarity Therapeutics Inc
05/04/202400:15GlobeNewswire Inc.Allarity Therapeutics Announces 1-for-20 Reverse Stock SplitNASDAQ:ALLRAllarity Therapeutics Inc
27/03/202423:30GlobeNewswire Inc.Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian CancerNASDAQ:ALLRAllarity Therapeutics Inc
25/03/202422:30GlobeNewswire Inc.Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)NASDAQ:ALLRAllarity Therapeutics Inc
09/03/202400:38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
08/03/202423:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALLRAllarity Therapeutics Inc
08/03/202423:15GlobeNewswire Inc.Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business UpdateNASDAQ:ALLRAllarity Therapeutics Inc
08/03/202413:45Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ALLRAllarity Therapeutics Inc
05/03/202408:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
02/03/202401:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
28/02/202422:00GlobeNewswire Inc.Allarity Therapeutics to Present at Biomarkers 2024NASDAQ:ALLRAllarity Therapeutics Inc
24/02/202408:09Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:ALLRAllarity Therapeutics Inc
15/02/202401:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
03/02/202409:03Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ALLRAllarity Therapeutics Inc
02/02/202408:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
27/01/202409:07Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ALLRAllarity Therapeutics Inc
26/01/202409:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ALLR

Your Recent History

BIT
S29108
Societe Generale Effekten
COIN
TYMUSD
NASDAQ
GUTS
Fractyl Health
COIN
POTTUST
X Protocol
COIN
CCAEUR
BIT
F18696
Vontobel Financial Produ...
ASX
NABPI
National Australia Bank
HUOB
ARGUSDT
Argentine Football Association F
COIN
DGTXETH
DigitexFutures
POLO
BTTBTC
BIT
S24962
SG ISSUER
ASX
CYLN
COIN
BTCBRBTC
BitcoinBrand
HUOB
TRBUSDT
Tellor Tributes
NASDAQ
EMLD
FTAC Emerald Acquisition
USOTC
LVCE
LiveCare (CE)
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved